Research Analysts Set Expectations for SRPT Q1 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report issued on Monday, January 6th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $1.90 per share for the quarter, down from their prior forecast of $1.98. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.16 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.63 EPS, Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at $2.83 EPS, FY2025 earnings at $9.95 EPS, Q1 2026 earnings at $3.04 EPS, Q2 2026 earnings at $3.56 EPS, Q3 2026 earnings at $3.53 EPS, Q4 2026 earnings at $3.53 EPS and FY2026 earnings at $13.66 EPS.

SRPT has been the subject of several other reports. Evercore ISI reduced their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Needham & Company LLC reduced their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research note on Wednesday, November 27th. Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, December 19th. Finally, UBS Group raised their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $126.27 on Thursday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics has a 52 week low of $102.15 and a 52 week high of $173.25. The company’s 50 day moving average price is $122.10 and its 200 day moving average price is $131.36. The company has a market capitalization of $12.06 billion, a PE ratio of 101.02 and a beta of 0.77.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky bought a new stake in Sarepta Therapeutics during the second quarter worth about $4,771,000. Simplify Asset Management Inc. raised its position in Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after purchasing an additional 88,474 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Summit Partners Public Asset Management LLC boosted its stake in Sarepta Therapeutics by 547.9% in the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.